Cortical Folding Defects as Markers of Poor Treatment Response in First-Episode Psychosis

IMPORTANCE At present, no reliable predictors exist to distinguish future responders from nonresponders to treatment during the first episode of psychosis. Among potential neuroimaging predictors of treatment response, gyrification represents an important marker of the integrity of normal cortical d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA psychiatry (Chicago, Ill.) Ill.), 2013-10, Vol.70 (10), p.1031-1040
Hauptverfasser: Palaniyappan, Lena, Marques, Tiago Reis, Taylor, Heather, Handley, Rowena, Mondelli, Valeria, Bonaccorso, Stefania, Giordano, Annalisa, McQueen, Grant, DiForti, Marta, Simmons, Andrew, David, Anthony S, Pariante, Carmine M, Murray, Robin M, Dazzan, Paola
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1040
container_issue 10
container_start_page 1031
container_title JAMA psychiatry (Chicago, Ill.)
container_volume 70
creator Palaniyappan, Lena
Marques, Tiago Reis
Taylor, Heather
Handley, Rowena
Mondelli, Valeria
Bonaccorso, Stefania
Giordano, Annalisa
McQueen, Grant
DiForti, Marta
Simmons, Andrew
David, Anthony S
Pariante, Carmine M
Murray, Robin M
Dazzan, Paola
description IMPORTANCE At present, no reliable predictors exist to distinguish future responders from nonresponders to treatment during the first episode of psychosis. Among potential neuroimaging predictors of treatment response, gyrification represents an important marker of the integrity of normal cortical development that may characterize, already at illness onset, a subgroup of patients with particularly poor outcome. OBJECTIVE To determine whether patients with first-episode psychosis who do not respond to 12 weeks of antipsychotic treatment already have significant gyrification defects at illness onset. DESIGN Case-control study with 12 weeks’ longitudinal follow-up to determine treatment response. SETTING Secondary psychiatric services in an inner-city area (South London, England). PARTICIPANTS A total of 126 subjects, including 80 patients presenting with first-episode psychosis and 46 healthy controls. Patients were scanned at the outset and received various antipsychotic medications in a naturalistic clinical setting. They were followed up for 12 weeks and classified as responders or nonresponders if they reached criteria for symptom remission, evaluated with the Psychiatric and Personal History Schedule. OBSERVATION Patients were exposed to naturalistic antipsychotic treatment for 12 weeks following a magnetic resonance imaging scan. MAIN OUTCOMES AND MEASURES Cortical gyrification was assessed using local gyrification index in a vertexwise fashion across the entire cortical surface with correction for multiple testing using permutation analysis. Differences in local gyrification index were assessed between responders, nonresponders, and healthy controls. The effect of diagnosis (affective vs nonaffective psychosis) on the local gyrification index was also investigated in responders and nonresponders. RESULTS Patients with first-episode psychosis showed a significant reduction in gyrification (hypogyria) across multiple brain regions compared with healthy controls. Interestingly, nonresponders showed prominent hypogyria at bilateral insular, left frontal, and right temporal regions when compared with responders (all clusters significant at P 
doi_str_mv 10.1001/jamapsychiatry.2013.203
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1440453279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>1727437</ama_id><sourcerecordid>3094147261</sourcerecordid><originalsourceid>FETCH-LOGICAL-a505t-78e0ae1c37867cfa0c0b87d24cc8a956ede55333769d4ba2651d194fb8f161613</originalsourceid><addsrcrecordid>eNpVkE1LAzEQhoMoWmr_gAcNiMet-dxkj1JbFRRFKuhpSbNZTW03a2Z76L83pVUxgZkcnpk3PAidUTKkhNDLuVmaFtb2w5suroeMUJ4K30M9RnOd5Yzr_d83ez1CA4A5SUcTIrg-REeMF0IWUvTQ2yjEzluzwJOwqHzzjq9d7WwH2AB-MPHTRcChxk8hRDyNznRL13T42UEbGnDYN3jiI3TZuPUQKoefNh8L4OEYHdRmAW6w6330MhlPR7fZ_ePN3ejqPjOSyC5T2hHjqOVK58rWhlgy06piwlptCpm7yknJOVd5UYmZYbmkFS1EPdM1zdPlfXS-3dvG8LVy0JXzsIpNiiypEERIzlSRKLWlbAwA0dVlG_3SxHVJSbmxWv63Wm6spsLT5Olu_2q2dNXv3I_DBFzsAANJZB1NYz38cUoTmROVuJMtl4L-0hVTgiv-DV4_jIs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1440453279</pqid></control><display><type>article</type><title>Cortical Folding Defects as Markers of Poor Treatment Response in First-Episode Psychosis</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Palaniyappan, Lena ; Marques, Tiago Reis ; Taylor, Heather ; Handley, Rowena ; Mondelli, Valeria ; Bonaccorso, Stefania ; Giordano, Annalisa ; McQueen, Grant ; DiForti, Marta ; Simmons, Andrew ; David, Anthony S ; Pariante, Carmine M ; Murray, Robin M ; Dazzan, Paola</creator><creatorcontrib>Palaniyappan, Lena ; Marques, Tiago Reis ; Taylor, Heather ; Handley, Rowena ; Mondelli, Valeria ; Bonaccorso, Stefania ; Giordano, Annalisa ; McQueen, Grant ; DiForti, Marta ; Simmons, Andrew ; David, Anthony S ; Pariante, Carmine M ; Murray, Robin M ; Dazzan, Paola</creatorcontrib><description>IMPORTANCE At present, no reliable predictors exist to distinguish future responders from nonresponders to treatment during the first episode of psychosis. Among potential neuroimaging predictors of treatment response, gyrification represents an important marker of the integrity of normal cortical development that may characterize, already at illness onset, a subgroup of patients with particularly poor outcome. OBJECTIVE To determine whether patients with first-episode psychosis who do not respond to 12 weeks of antipsychotic treatment already have significant gyrification defects at illness onset. DESIGN Case-control study with 12 weeks’ longitudinal follow-up to determine treatment response. SETTING Secondary psychiatric services in an inner-city area (South London, England). PARTICIPANTS A total of 126 subjects, including 80 patients presenting with first-episode psychosis and 46 healthy controls. Patients were scanned at the outset and received various antipsychotic medications in a naturalistic clinical setting. They were followed up for 12 weeks and classified as responders or nonresponders if they reached criteria for symptom remission, evaluated with the Psychiatric and Personal History Schedule. OBSERVATION Patients were exposed to naturalistic antipsychotic treatment for 12 weeks following a magnetic resonance imaging scan. MAIN OUTCOMES AND MEASURES Cortical gyrification was assessed using local gyrification index in a vertexwise fashion across the entire cortical surface with correction for multiple testing using permutation analysis. Differences in local gyrification index were assessed between responders, nonresponders, and healthy controls. The effect of diagnosis (affective vs nonaffective psychosis) on the local gyrification index was also investigated in responders and nonresponders. RESULTS Patients with first-episode psychosis showed a significant reduction in gyrification (hypogyria) across multiple brain regions compared with healthy controls. Interestingly, nonresponders showed prominent hypogyria at bilateral insular, left frontal, and right temporal regions when compared with responders (all clusters significant at P &lt; .05). These effects were present for both affective and nonaffective psychoses. CONCLUSIONS AND RELEVANCE Gyrification appears to be a useful predictor of antipsychotic treatment response. Early neurodevelopmental aberrations may predict unfavorable prognosis in psychosis, irrespective of the existing diagnostic boundaries.</description><identifier>ISSN: 2168-622X</identifier><identifier>EISSN: 2168-6238</identifier><identifier>DOI: 10.1001/jamapsychiatry.2013.203</identifier><identifier>PMID: 23945954</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Adult ; Antipsychotic Agents - therapeutic use ; Biological and medical sciences ; Biomarkers ; Brain ; Case-Control Studies ; Cerebral Cortex - pathology ; Female ; Humans ; Male ; Medical imaging ; Medical sciences ; Mental disorders ; Neuroimaging ; Psychiatry ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychosis ; Psychotic Disorders - diagnosis ; Psychotic Disorders - drug therapy ; Psychotic Disorders - pathology ; Psychotropic drugs ; Treatment Failure</subject><ispartof>JAMA psychiatry (Chicago, Ill.), 2013-10, Vol.70 (10), p.1031-1040</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright American Medical Association Oct 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a505t-78e0ae1c37867cfa0c0b87d24cc8a956ede55333769d4ba2651d194fb8f161613</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamapsychiatry/articlepdf/10.1001/jamapsychiatry.2013.203$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2013.203$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,780,784,3338,27922,27923,76259,76262</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27805607$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23945954$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Palaniyappan, Lena</creatorcontrib><creatorcontrib>Marques, Tiago Reis</creatorcontrib><creatorcontrib>Taylor, Heather</creatorcontrib><creatorcontrib>Handley, Rowena</creatorcontrib><creatorcontrib>Mondelli, Valeria</creatorcontrib><creatorcontrib>Bonaccorso, Stefania</creatorcontrib><creatorcontrib>Giordano, Annalisa</creatorcontrib><creatorcontrib>McQueen, Grant</creatorcontrib><creatorcontrib>DiForti, Marta</creatorcontrib><creatorcontrib>Simmons, Andrew</creatorcontrib><creatorcontrib>David, Anthony S</creatorcontrib><creatorcontrib>Pariante, Carmine M</creatorcontrib><creatorcontrib>Murray, Robin M</creatorcontrib><creatorcontrib>Dazzan, Paola</creatorcontrib><title>Cortical Folding Defects as Markers of Poor Treatment Response in First-Episode Psychosis</title><title>JAMA psychiatry (Chicago, Ill.)</title><addtitle>JAMA Psychiatry</addtitle><description>IMPORTANCE At present, no reliable predictors exist to distinguish future responders from nonresponders to treatment during the first episode of psychosis. Among potential neuroimaging predictors of treatment response, gyrification represents an important marker of the integrity of normal cortical development that may characterize, already at illness onset, a subgroup of patients with particularly poor outcome. OBJECTIVE To determine whether patients with first-episode psychosis who do not respond to 12 weeks of antipsychotic treatment already have significant gyrification defects at illness onset. DESIGN Case-control study with 12 weeks’ longitudinal follow-up to determine treatment response. SETTING Secondary psychiatric services in an inner-city area (South London, England). PARTICIPANTS A total of 126 subjects, including 80 patients presenting with first-episode psychosis and 46 healthy controls. Patients were scanned at the outset and received various antipsychotic medications in a naturalistic clinical setting. They were followed up for 12 weeks and classified as responders or nonresponders if they reached criteria for symptom remission, evaluated with the Psychiatric and Personal History Schedule. OBSERVATION Patients were exposed to naturalistic antipsychotic treatment for 12 weeks following a magnetic resonance imaging scan. MAIN OUTCOMES AND MEASURES Cortical gyrification was assessed using local gyrification index in a vertexwise fashion across the entire cortical surface with correction for multiple testing using permutation analysis. Differences in local gyrification index were assessed between responders, nonresponders, and healthy controls. The effect of diagnosis (affective vs nonaffective psychosis) on the local gyrification index was also investigated in responders and nonresponders. RESULTS Patients with first-episode psychosis showed a significant reduction in gyrification (hypogyria) across multiple brain regions compared with healthy controls. Interestingly, nonresponders showed prominent hypogyria at bilateral insular, left frontal, and right temporal regions when compared with responders (all clusters significant at P &lt; .05). These effects were present for both affective and nonaffective psychoses. CONCLUSIONS AND RELEVANCE Gyrification appears to be a useful predictor of antipsychotic treatment response. Early neurodevelopmental aberrations may predict unfavorable prognosis in psychosis, irrespective of the existing diagnostic boundaries.</description><subject>Adult</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Brain</subject><subject>Case-Control Studies</subject><subject>Cerebral Cortex - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medical sciences</subject><subject>Mental disorders</subject><subject>Neuroimaging</subject><subject>Psychiatry</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychosis</subject><subject>Psychotic Disorders - diagnosis</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Psychotic Disorders - pathology</subject><subject>Psychotropic drugs</subject><subject>Treatment Failure</subject><issn>2168-622X</issn><issn>2168-6238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE1LAzEQhoMoWmr_gAcNiMet-dxkj1JbFRRFKuhpSbNZTW03a2Z76L83pVUxgZkcnpk3PAidUTKkhNDLuVmaFtb2w5suroeMUJ4K30M9RnOd5Yzr_d83ez1CA4A5SUcTIrg-REeMF0IWUvTQ2yjEzluzwJOwqHzzjq9d7WwH2AB-MPHTRcChxk8hRDyNznRL13T42UEbGnDYN3jiI3TZuPUQKoefNh8L4OEYHdRmAW6w6330MhlPR7fZ_ePN3ejqPjOSyC5T2hHjqOVK58rWhlgy06piwlptCpm7yknJOVd5UYmZYbmkFS1EPdM1zdPlfXS-3dvG8LVy0JXzsIpNiiypEERIzlSRKLWlbAwA0dVlG_3SxHVJSbmxWv63Wm6spsLT5Olu_2q2dNXv3I_DBFzsAANJZB1NYz38cUoTmROVuJMtl4L-0hVTgiv-DV4_jIs</recordid><startdate>20131001</startdate><enddate>20131001</enddate><creator>Palaniyappan, Lena</creator><creator>Marques, Tiago Reis</creator><creator>Taylor, Heather</creator><creator>Handley, Rowena</creator><creator>Mondelli, Valeria</creator><creator>Bonaccorso, Stefania</creator><creator>Giordano, Annalisa</creator><creator>McQueen, Grant</creator><creator>DiForti, Marta</creator><creator>Simmons, Andrew</creator><creator>David, Anthony S</creator><creator>Pariante, Carmine M</creator><creator>Murray, Robin M</creator><creator>Dazzan, Paola</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20131001</creationdate><title>Cortical Folding Defects as Markers of Poor Treatment Response in First-Episode Psychosis</title><author>Palaniyappan, Lena ; Marques, Tiago Reis ; Taylor, Heather ; Handley, Rowena ; Mondelli, Valeria ; Bonaccorso, Stefania ; Giordano, Annalisa ; McQueen, Grant ; DiForti, Marta ; Simmons, Andrew ; David, Anthony S ; Pariante, Carmine M ; Murray, Robin M ; Dazzan, Paola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a505t-78e0ae1c37867cfa0c0b87d24cc8a956ede55333769d4ba2651d194fb8f161613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Brain</topic><topic>Case-Control Studies</topic><topic>Cerebral Cortex - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medical sciences</topic><topic>Mental disorders</topic><topic>Neuroimaging</topic><topic>Psychiatry</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychosis</topic><topic>Psychotic Disorders - diagnosis</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Psychotic Disorders - pathology</topic><topic>Psychotropic drugs</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Palaniyappan, Lena</creatorcontrib><creatorcontrib>Marques, Tiago Reis</creatorcontrib><creatorcontrib>Taylor, Heather</creatorcontrib><creatorcontrib>Handley, Rowena</creatorcontrib><creatorcontrib>Mondelli, Valeria</creatorcontrib><creatorcontrib>Bonaccorso, Stefania</creatorcontrib><creatorcontrib>Giordano, Annalisa</creatorcontrib><creatorcontrib>McQueen, Grant</creatorcontrib><creatorcontrib>DiForti, Marta</creatorcontrib><creatorcontrib>Simmons, Andrew</creatorcontrib><creatorcontrib>David, Anthony S</creatorcontrib><creatorcontrib>Pariante, Carmine M</creatorcontrib><creatorcontrib>Murray, Robin M</creatorcontrib><creatorcontrib>Dazzan, Paola</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>JAMA psychiatry (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Palaniyappan, Lena</au><au>Marques, Tiago Reis</au><au>Taylor, Heather</au><au>Handley, Rowena</au><au>Mondelli, Valeria</au><au>Bonaccorso, Stefania</au><au>Giordano, Annalisa</au><au>McQueen, Grant</au><au>DiForti, Marta</au><au>Simmons, Andrew</au><au>David, Anthony S</au><au>Pariante, Carmine M</au><au>Murray, Robin M</au><au>Dazzan, Paola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cortical Folding Defects as Markers of Poor Treatment Response in First-Episode Psychosis</atitle><jtitle>JAMA psychiatry (Chicago, Ill.)</jtitle><addtitle>JAMA Psychiatry</addtitle><date>2013-10-01</date><risdate>2013</risdate><volume>70</volume><issue>10</issue><spage>1031</spage><epage>1040</epage><pages>1031-1040</pages><issn>2168-622X</issn><eissn>2168-6238</eissn><abstract>IMPORTANCE At present, no reliable predictors exist to distinguish future responders from nonresponders to treatment during the first episode of psychosis. Among potential neuroimaging predictors of treatment response, gyrification represents an important marker of the integrity of normal cortical development that may characterize, already at illness onset, a subgroup of patients with particularly poor outcome. OBJECTIVE To determine whether patients with first-episode psychosis who do not respond to 12 weeks of antipsychotic treatment already have significant gyrification defects at illness onset. DESIGN Case-control study with 12 weeks’ longitudinal follow-up to determine treatment response. SETTING Secondary psychiatric services in an inner-city area (South London, England). PARTICIPANTS A total of 126 subjects, including 80 patients presenting with first-episode psychosis and 46 healthy controls. Patients were scanned at the outset and received various antipsychotic medications in a naturalistic clinical setting. They were followed up for 12 weeks and classified as responders or nonresponders if they reached criteria for symptom remission, evaluated with the Psychiatric and Personal History Schedule. OBSERVATION Patients were exposed to naturalistic antipsychotic treatment for 12 weeks following a magnetic resonance imaging scan. MAIN OUTCOMES AND MEASURES Cortical gyrification was assessed using local gyrification index in a vertexwise fashion across the entire cortical surface with correction for multiple testing using permutation analysis. Differences in local gyrification index were assessed between responders, nonresponders, and healthy controls. The effect of diagnosis (affective vs nonaffective psychosis) on the local gyrification index was also investigated in responders and nonresponders. RESULTS Patients with first-episode psychosis showed a significant reduction in gyrification (hypogyria) across multiple brain regions compared with healthy controls. Interestingly, nonresponders showed prominent hypogyria at bilateral insular, left frontal, and right temporal regions when compared with responders (all clusters significant at P &lt; .05). These effects were present for both affective and nonaffective psychoses. CONCLUSIONS AND RELEVANCE Gyrification appears to be a useful predictor of antipsychotic treatment response. Early neurodevelopmental aberrations may predict unfavorable prognosis in psychosis, irrespective of the existing diagnostic boundaries.</abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>23945954</pmid><doi>10.1001/jamapsychiatry.2013.203</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-622X
ispartof JAMA psychiatry (Chicago, Ill.), 2013-10, Vol.70 (10), p.1031-1040
issn 2168-622X
2168-6238
language eng
recordid cdi_proquest_journals_1440453279
source MEDLINE; American Medical Association Journals
subjects Adult
Antipsychotic Agents - therapeutic use
Biological and medical sciences
Biomarkers
Brain
Case-Control Studies
Cerebral Cortex - pathology
Female
Humans
Male
Medical imaging
Medical sciences
Mental disorders
Neuroimaging
Psychiatry
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Psychosis
Psychotic Disorders - diagnosis
Psychotic Disorders - drug therapy
Psychotic Disorders - pathology
Psychotropic drugs
Treatment Failure
title Cortical Folding Defects as Markers of Poor Treatment Response in First-Episode Psychosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T06%3A07%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cortical%20Folding%20Defects%20as%20Markers%20of%20Poor%20Treatment%20Response%20in%20First-Episode%20Psychosis&rft.jtitle=JAMA%20psychiatry%20(Chicago,%20Ill.)&rft.au=Palaniyappan,%20Lena&rft.date=2013-10-01&rft.volume=70&rft.issue=10&rft.spage=1031&rft.epage=1040&rft.pages=1031-1040&rft.issn=2168-622X&rft.eissn=2168-6238&rft_id=info:doi/10.1001/jamapsychiatry.2013.203&rft_dat=%3Cproquest_cross%3E3094147261%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1440453279&rft_id=info:pmid/23945954&rft_ama_id=1727437&rfr_iscdi=true